SCT to present at 2018 Antibody Engineering & Therapeutics Conference in San Diego

30 November 2018

Single Cell Technology announced today that Chun-Nan Chen, Ph.D., CEO and CSO, will present at the 2018 Antibody Engineering & Therapeutics conference in San Diego, CA, December 10-13, 2018. Dr. Chen's talk will present case studies and data output from AbTheneum™. Details on the presentation are available on the Antibody Engineering & Therapeutics website and as follows:

Title: AbTheneum Technology Delivers Antibody Metadata: Native Sequence Pairs Correlated with Binding Activity Against Your Targeted Region of Antigen

Date & Time: Tuesday, December 11, 1:45 pm - 2:15 pm

Single Cell Technology will also be exhibiting at Booth 316 in the exhibition hall at the conference. Come meet our team and ask us about your project needs!

If you haven't registered for Antibody Engineering yet, use our VIP discount code to receive a 10% discount on current registration costs!

VIP code D18172SPEX

See you in San Diego!

Recent News

New mechanism that predicts a competitive advantage to SARS-CoV-2 virus carrying the D614G spike mutation

Jun 15, 2020

A manuscript studying a prominent mutation in SARS-CoV-2 has been published on a preprint server by partners Single Cell Technology and Antibody Solutions.

Read More+

SCT to present candidate selection workflow at Antibody Engineering & Therapeutics

Jun 15, 2020

SCT to present a candidate selection workflow of AbTheneum output at Antibody Engineering & Therapeutics using BCMA, TIGIT, and TIM3 to demonstrate the year-long effort. The presentation will be given on Wednesday, December 11 at the Marriott Marquis in San Diego…

Read More+

ACROBiosystems brings high affinity anti-BCMA antibodies, attending Fifteenth Annual PEGS Boston 2019

Apr 8, 2019

ACROBiosystems, a leading manufacturer of recombinant proteins and critical reagents to the biopharma industry, today announced at the PEGS – Protein Engineering Summit the successful completion of isolation and characterization of a large panel of anti-human BCMA antibodies for the purpose of treating multiple myeloma cancer.

Read More+